Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia

Br J Haematol. 2015 Jun;169(5):756-9. doi: 10.1111/bjh.13248. Epub 2014 Dec 17.

Authors

Gaku Oshikawa¹, Kazuhiko Kakihana², Makoto Saito³, Jun Aoki¹, Yuho Najima¹, Takeshi Kobayashi¹, Noriko Doki¹, Hisashi Sakamaki¹, Kazuteru Ohashi¹

Affiliations

¹ Division of Haematology, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo, Japan.
² Division of Haematology, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo, Japan. kakihana@cick.jp.
³ Divisions of Clinical Research Support, Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital, Tokyo, Japan.

PMID: 25522128
DOI: 10.1111/bjh.13248

No abstract available

Keywords: acute myeloid leukaemia; allogeneic haematopoietic stem cell transplantation; azacitidine; gemtuzumab ozogamicin; maintenance therapy.

Publication types

Letter

MeSH terms

Aminoglycosides / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Azacitidine / administration & dosage
Gemtuzumab
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy
Maintenance Chemotherapy
Treatment Outcome

Substances

Aminoglycosides
Antibodies, Monoclonal, Humanized
Gemtuzumab
Azacitidine